Skip to main content
Fig. 6 | BMC Neurology

Fig. 6

From: Immunological and short-term brain volume changes in relapsing forms of multiple sclerosis treated with interferon beta-1a subcutaneously three times weekly: an open-label two-arm trial

Fig. 6

IL-17 F-expressing CD4+ T cells and WM volume changes in RRMS. Decreased percentage of IL-17 F-expressing CD4+ T cells from baseline to 6 months correlated with decreased WM volume from baseline to 6 months in treated patients with RRMS. IL interleukin; RRMS relapsing–remitting multiple sclerosis; WM white matter

Back to article page